CDK4/6 Inhibitors for Breast Cancer: Who Does, Doesn’t Benefit?

In an effort to improve patient selection for CDK4/6 inhibitor use for metastatic breast cancer, US FDA staff conducted a pooled analysis of clinical trial data.
Medscape Medical News …read more